Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Axel Schulenburg1,2,7*, Katharina Blatt3, Sabine Cerny-Reiterer2,3, Irina Sadovnik3, Harald Herrmann2,4, Brigitte Marian2,5, Thomas W Grunt2,6, Christoph C Zielinski2,6 and Peter Valent2,3

Abstract

Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating (curative) potential of various drugs. However, although diverse CSC markers and targets have been identified, several questions remain, such as the origin and evolution of CSC, mechanisms underlying resistance of CSC against various targeted drugs, and the biochemical basis and function of stroma cell-CSC interactions in the so-called ‘stem cell niche.’ Additional aspects that have to be taken into account when considering CSC elimination as primary treatment-goal are the genomic plasticity and extensive subclone formation of CSC. Notably, various cell fractions with different combinations of molecular aberrations and varying proliferative potential may display CSC function in a given neoplasm, and the related molecular complexity of the genome in CSC subsets is considered to contribute essentially to disease evolution and acquired drug resistance. In the current article, we discuss new developments in the field of CSC research and whether these new concepts can be exploited in clinical practice in the future.

Keywords: Cancer stem cells, Targeted therapy, Drug resistance

Introduction

The principle concept of cancer stem cells (CSC) has gained increasing acceptance in recent years [1-10]. By definition, CSC exhibit self-renewal activity and long-term cancer-propagating capacity [1-9]. By contrast, more mature clonal cells in the same neoplasm have limited proliferative potential. In leukemias, CSC are also known as leukemic stem cells (LSC) [5,8,11-18]. The concept of neoplastic stem cells may provide explanations for the failure of various cytoreductive agents to produce long-lasting responses in patients [1-9,11,15-18]. Notably, in many instances, anti-neoplastic drugs act on more mature neoplastic cells rather than CSC/LSC, a phenomenon that is explained in part by the fact that these cells exhibit intrinsic resistance [19-23]. Moreover, CSC often develop acquired drug resistance and thus produce more malignant subclones over time [11,24-26].

All these observations point to the need to develop new CSC-eliminating treatment strategies through which cure rates and survival can be improved [16,27-31]. In other words, CSC have been recognized as a major ‘target cell population’ in oncology in recent years, and considerable effort has been made to identify novel CSC markers and target expression profiles and to measure responses of these cells to various targeted drugs.

The present article provides a summary of our knowledge on CSC/LSC, with special focus on the possibility to translate CSC/LSC-targeting treatment concepts into clinical application. Unless otherwise stated, this article refers to CSC/LSC in primary human malignancies. With regard to cell line models and engineered CSC-like
cells or other more ‘artificial’ models that may also support CSC research, we refer to the published literature.

**Definition and function of cancer stem cells**

In contrast to more mature cancer cells, CSC are self-renewing cells with long-term proliferative potential [1-9,11]. As a result, CSC can maintain a given neoplasm for prolonged time periods. In most cases, these cells can also produce a cancer (CSC) or leukemia (LSC) in immunodeficient mice (xenotransplantation model) which enables their detection and quantification [1-9,32,33]. Previous studies have used non-obese diabetic mice with severe combined immunodeficiency (NOD/SCID) [1-3,5,6,32,33]. In several tumor models, this mouse strain is a sufficient or even a preferable model to study CSC biology [34]. However, more recent data suggest that in several primary malignancies, NOD/SCID with loss-of-function-mutated IL-2Rgamma chain or IL-2Rgamma chain-knock out NOD/shi-SCID mice (NSG or NOG mice) provide superior engraftment rates [35-38]. Therefore, many current studies on primary CSC/LSC employ NSG mice. Depending on the type of disease, neoplastic cells are injected intravenously, subcutaneously, or directly into solid organs (orthotopic application) [27,39-44]. An important point is that ‘short-term engraftment’ (or just simple maintenance) of tumor-leukemic cells has to be differentiated from long-term engraftment, only the latter being indicative of the presence of functionally active (self-renewing) CSC. Long-term engraftment and growth of cancers/leukemias is best demonstrable by recovering engrafted cells from primary recipient mice and injecting these cells into secondary recipient animals [32,39,40,42,43,45-47].

Despite advanced technologies and novel mouse models, xenotransplantation assays for human CSC have several limitations. First, the microenvironment is often species-specific or tumor-specific. Second, in a neoplasm with low growth-rate (for example, indolent/low-grade/chronic tumor; premalignant neoplasms), the development phase of the neoplasm may exceed the lifetime of a mouse. Moreover, the CSC pool is composed of heterogeneous populations of tumor-initiating cells with subclone-specific molecular properties and varying growth characteristics in vivo [11,25,26,28,48]. Some of the CSC may be recognized (and eliminated) by the residual immune system of xeno-transplanted mice [37,38]. On the other hand, the lack of a natural immune system and thus tumor immune surveillance in highly immunodeficient mice may facilitate the uncontrolled expansion of clinically irrelevant sub-clones. Therefore, several attempts are currently made to establish NSG-mouse models harboring a human immune system.

A frequently discussed alternative to in vivo xenotransplantation studies are in vitro long-term culture experiments to study the growth and maintenance of CSC [47,49-53]. Although helpful as a screen approach, these assays are not sufficient for evaluating the in vivo self-renewal capacity of ‘true’ CSC. Several in vitro assays employ stromal cells which may provide some of the ‘niche-factors’ required for long-term growth CSC [47,49-53]. Solid tumor cells often grow in ‘spheres’ or clusters for prolonged time periods in such assays [47,49-53]. However, as mentioned above, the available in vitro assays cannot replace in vivo xenotransplantation models when long-term self renewal and tumor propagation should be examined.

**Identification and enrichment of CSC/LSC**

Several different approaches, through which CSC/LSC can be identified and enriched in primary cancer/leukemia samples, have been developed in the past [1-3,5-7,11,13,27,54-61]. A widely applied strategy is to use antibodies directed against certain cell surface antigens that are (or are not) expressed on CSC [1-3,5-7,9,11-13,27]. Expression of surface antigens is best determined by multicolor flow cytometry. Enrichment of CSC/LSC can be performed by fluorescence-activated cell sorting (FACS) or magnetic cell sorting [1-9,13,15-18,62-69]. Both techniques have certain limitations. One general problem is that the ‘so-called’ stem cell markers are often not specific for CSC or LSC. Likewise, the stem cell-related antigen CD34 is not only expressed on hematopoietic stem cells but also on myeloid progenitor cells and endothelial cells, and KIT is not only expressed on hematopoietic stem- and progenitor cells but also on mast cells, germ cells, and melanocytes [70,71]. Therefore, it is essential to apply combinations of antibodies when detecting and analyzing CSC/LSC in various tissues. Usually, one or two organ-specific markers are employed to confirm the primary origin of cells (Tables 1 and 2). The panhematopoietic marker CD45 is widely used to confirm the hematopoietic origin of cells or to exclude leukocytes in primary fractions obtained from solid tumors. Additional antibodies are applied to delineate CSC from more mature neoplastic cells [1-3,5-7,9,11-13,27,65-69,72,73]. In case of myeloid leukemias, the antigen profiles of more mature cells are well defined, and the approach to deplete these (Lin+) cells from LSC is well established. However, in certain leukemias, LSC may aberrantly express one or even several of the ‘lineage-related’ antigens. In such leukemias, application of the ‘Lin-cocktail’ may lead to a loss of LSC subsets. Another problem is that antibody-bound cells may be detected and eliminated by the residual immune system of NOD/SCID mice. This problem has been outlined in acute myeloid leukemia (AML) where CD38+ cells (CD38 antibody-laden) may be cleared by the residual immune...
system of NOD/SCID mice [38]. The problem has been addressed by switching from NOD/SCID mice to NSG (or NOG) mice that lack a functionally active cytokine receptor gamma chain [35-38]. As mentioned above, the lack of a natural immune system in these models is a remaining issue that will hopefully be solved by introducing a humanized immune system into these mice. Another caveat is that some of the antibody preparations used to define CSC may induce apoptosis in cancer cells [74].

In solid tumors, a general problem is that for most neoplasms, robust markers discriminating between more mature and immature cells are not available. In colorectal cancer and some other solid tumors, the Wnt target gene LGR5 has been described as a potential CSC marker [121,122]. Other markers, such as CD44, are broadly expressed on tumor cells and also in other cell types (for example, leukocytes) present in the same organ sites. Another problem is that several CSC-homing receptors and their ligands are species specific which may prevent homing of CSC to their specific microenvironment (CSC niche) in mice. Regulation of growth and development of CSC/LSC

So far, little is known about the regulation of growth and survival of CSC/LSC in hematopoietic and non-hematopoietic malignancies. The development phase of CSC may often last for years if not decades [28,48,54,128]. In an early phase (pre-phase) of cancer or leukemia development, neoplastic stem cells may be slowly cycling cells that produce small-sized subclones [11,28,54,128]. At this early hypothetical stage of cancer evolution, it may be preferable to call these cells pre-malignant neoplastic stem cells (NSC) rather than CSC/
LSC [24,28,128-131]. Later, when these premalignant cells have accumulated a sufficient number of molecular lesions (defects) and thereby have ‘learned’ how to escape all relevant surveillance mechanisms, their progeny can expand and form an overt malignancy within short time, so that the term malignant NSC (= CSC or LSC in leukemias) is appropriate [28,48,128,130,132] (Table 3). In early phases of NSC evolution (premalignant stage), the mechanisms and molecules regulating growth, survival, and asymmetrical cell division, may be similar if not the same compared to that in normal stem cells. These factors include cytokines and cytokine-receptors, niche-related factors, including stem cell-homing and chemotactic molecules, pro- and anti-apoptotic molecules, and signaling pathways involved in the regulation of self-renewal and proliferation [133-135]. Later, when NSC-derived neoplastic clones expand to an overt malignancy, several ‘physiologic’ mechanisms controlling growth and differentiation of normal (and premalignant neoplastic) stem cells may no longer work to prevent clonal expansion [28,48,128,130,136-138].

Cytokine regulation of NSC (CSC/LSC)

A number of recent data suggest that the cytokine network is involved in the regulation of self-renewal, growth, survival, and differentiation of NSC [64,69,125]. As mentioned above, the cytokines that regulate growth and function of premalignant NSC may be similar or the same as that regulating growth of normal stem cells. Likewise, in myeloid leukemias, NSC/LSC express receptors for various regulators of normal stem cells, including the IL-3 receptor (CD123/CD131), SCF receptor KIT (CD117), or G-CSF receptor (CD114) [64,69,139]. It has also been described that epidermal growth factor (EGF) receptor family members, including HER2, are expressed on epithelial NSC/CSC, such as mammary CSC [140,141]. There is also evidence that insulin-like growth factor (IGF) receptors and fibroblast growth factor (FGF) receptors play an important role in solid tumors and may be expressed on solid tumor CSC [142-144]. At least in leukemias, the cytokine ligands that bind to these receptors trigger proliferation of LSC-enriched cell fractions [139]. Depending on the type and phase of disease, these cytokines also promote differentiation and maturation of LSC. However, most of these cytokines may not cause self-renewal in LSC. Some of these cytokines, such as IL-3, are also produced in clonal cells and may thus act as autocrine growth regulators of LSC [17,87,145,146]. LSC are also considered to respond to various chemokines. In line with this assumption, LSC express chemokine receptors such as CXCR4 [39,147-150]. A clinically important question is whether premalignant NSC or CSC/LSC express receptors for erythropoietin (EPO), granulocyte colony-stimulating

| Table 2 Phenotype of CSC-enriched fractions of neoplastic cells in solid tumors a |
| Neoplasm        | Phenotype of CSC-rich cell fraction | Reference |
|-----------------|------------------------------------|-----------|
| Breast cancer   | CD326+/CD45−/CD44+/CD24−           | [40]      |
|                 | CD44+/CD49f+/CD133+                | [92]      |
|                 | CD326+/CD44+/CD47+/MET+            | [93]      |
|                 | CD29f                              |           |
| Gastric cancer  | CD326+/CD44+                       | [94]      |
|                 | CD49f+                             | [95]      |
|                 | CD90+                              | [96]      |
|                 | LGR5+                              | [97]      |
|                 | CD44+                              |           |
| Colon cancer    | CD326+/CD44+/CD166+                | [99]      |
|                 | CD44+/CD49f+/CD133+                | [100]     |
|                 | LGR5+                              | [101]     |
|                 | CD133+                             | [47]      |
| SCLC            | CD133+                             | [102]     |
| NSCLC           | CD133+                             | [103]     |
| Pancreatic cancer| CD44+/CD24+/CD326+                | [43]      |
|                 | CD133+/CXCR4+                      | [39]      |
| HCC             | CD326                               | [104]     |
|                 | CD133+                             | [105]     |
|                 | CD44+/CD90+                        | [44]      |
| Glioblastoma    | CD133+                             | [42]      |
|                 | CD15+/CD133+                       | [106]     |
|                 | CD15+/CD133+                       | [106]     |
|                 | CD133+                              | [107]     |
| Ewing’s sarcoma  | CD133+                             | [108]     |
| Osteosarcoma    | CD133+                             | [109]     |
|                 | CD117+/STRO-1+                     | [110]     |
|                 | CD271+                             | [111]     |
| Ovarian cancer  | CD24+/CD44+/CD326+                 | [112]     |
|                 | CD44+/CD117+                       | [113]     |
|                 | CD133+                             | [114]     |
| Prostate cancer | CD44+/CD49f/CD326+                 | [115]     |
|                 | CD44+/CD24−                        | [116]     |
|                 | CD44+/CD133+                       | [117]     |
| Melanoma        | CD271+                             | [118]     |
|                 | ABCB5+                             | [119]     |
|                 | EPOR+                              | [120]     |

NSC, neoplastic stem cells; LGR5, Leucine-rich repeat-containing G-protein coupled receptor 5; SCLC, small cell lung cancer; n.k., not known; NSCL, non-small cell lung cancer; HCC, hepatocellular carcinoma; EPOR, erythropoietin receptor. aExpression of NSC markers refers to primary human cells tested in xenotransplantation assays and/or in a sphere-formation assay. bCD326 is not detectable on human NSC by flow cytometry.
factor (G-CSF), or granulocyte/macrophage colony-stimulating factor (GM-CSF). These cytokines are often administered in tumor patients in order to correct disease-related anemia or to accelerate neutrophil production after chemotherapy. In AML as well as in the myelodysplastic syndromes (MDS), NSC/LSC indeed express receptors for G-CSF and sometimes also for GM-CSF [139]. By contrast, NSC/LSC usually do not express EPO receptors in these malignancies. However, the EPO receptor may be expressed on CSC in a few solid tumors as well as in melanoma-initiating cells [120,151-153].

Table 4 shows a summary of cytokine receptors expressed on CSC and LSC in various malignancies. **Oncogenic signaling pathways in NSC (CSC/LSC)**

Growth and function of NSC, including self-renewal and malignant expansion, are considered to depend on a complex network of signaling cascades and molecules. Oncogenic signaling is considered to derive from three distinct classes of molecules, i) the driver lesions (primary oncogenic kinases) that are often disease-specific or at least disease-related, like BCR/ABL in chronic myeloid leukemia (CML), ii) broadly expressed mutated oncogenic kinases, and iii) cytokine-activated stem cell kinases that play a role in survival or/and growth of NSC (example: wt KIT in leukemias). The downstream signaling networks of ‘i’, ‘ii’, and ‘iii’ are in part

### Table 3 Classification of neoplastic stem cells (NSC)

| Defining properties                | Premalignant NSC | Malignant NSC = CSC/LSC |
|------------------------------------|------------------|------------------------|
| Self-renewal                       | Yes              | Yes                    |
| Cell cycle                         | Dormant or very slowly cycling | Slowly cycling or more rapidly cycling |
| Immediate tumor-initiating potential | No*              | Yes                    |
| Long-term tumor-initiating potential | Facultative potential*       | Yes                    |
| Numbers of somatic acquired molecular lesions/ mutations | Relatively low | Relatively high |
| Drug response                      | Intrinsic resistance (based in part on quiescence) | Intrinsic and often also acquired resistance in malignant subclones |

*The potential of a NSC to produce a neoplastic condition does not mean that this cell can form a tumor within a certain time period; however, after a certain latency period, when a sufficient number of molecular lesions have been accumulated, these premalignant NSC may transform to fully malignant NSC (= CSC/LSC) that have immediate tumor-initiating capacity in vivo in patients as well as in NSG mice. In a subset of patients, premalignant NSC will never convert into fully malignant NSC (= CSC/LSC). NSC, neoplastic stem cells; CSC/LSC, cancer stem cells/leukemic stem cells.

### Table 4 Cytokine/chemokine receptors detectable on neoplastic stem cells (NSC)

| Malignancy     | Cytokine receptors expressed on NSC                                                                 |
|----------------|------------------------------------------------------------------------------------------------------|
| AML            | IL-2RA [154], IL-3RA [155], G-CSFR [156], FLT3 [157], SCFR/KIT [158], CXCR4 [159]                  |
| MDS            | G-CSFR [160], SCFR/KIT, CXCR4 [161]                                                                   |
| MPN            | G-CSFR [160], SCFR/KIT [162], CXCR4 [163]                                                             |
| Ph + CML       | IL-2RA [83], IL-3RA [17], G-CSFR [160], GM-CSFR [164], SCFR/KIT [165], IL-1RAP [87], CXCR4 [166]     |
| Ph + ALL       | IL-2RA [167], IL-3RA [168], CXCR4 [169]                                                               |
| Myeloma        | CXCR4 [170]                                                                                            |
| Breast cancer  | EGFR [171], ERBB2/Her2 [172], FGFR2 [173], TGFβR [174], MET [93]                                      |
| Gastric cancer | EGFR [175], ERBB2/Her2 [176]                                                                          |
| Colon cancer   | EGFR [177], CXCR4 [178], IGF1R [179], TGFβR [180]                                                     |
| SCLC           | EGFR [181]                                                                                            |
| Pancreatic cancer | EGFR [182], CXCR4 [39]                                                                                     |
| HCC            | EGFR, IGF1R [183]                                                                                       |
| Glioblastoma   | EGFR [184], PDGFRb [185], CXCR4 [186], TGFβR [187], MET [188]                                         |
| Ovarian cancer | EGFR [189], ERBB2/Her2 [190], IGF1R, TGFβR [191]                                                      |
| Prostate cancer | CXCR4 [192]                                                                                           |
| Melanoma       | CXCR1 [193], EPOR [120]                                                                                 |

AML, acute myeloid leukemia; IL, interleukin; G-CSFR, granulocyte colony-stimulating factor receptor; SCF, stem cell factor receptor; Ph+, Philadelphia chromosome-positive; CML, chronic myeloid leukemia; GM-CSF, granulocyte- macrophage colony-stimulating factor; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; EGFR, epidermal growth factor receptor; TGFβR, transforming growth factor β receptor; IGF1R, insulin-like growth factor 1 receptor; SCLC, small cell lung cancer; NSCL, non-small cell lung cancer; n.k., not known; HCC, hepatocellular carcinoma; PDGFR, platelet-derived growth factor receptor; NGFR, nerve growth factor receptor; EPOR, erythropoietin receptor.
overlapping, may often complement each other, and may sometimes even produce synergistic effects on downstream activation and thus oncogenesis [165,194-196]. In an early phase of cancer evolution, the driver mutation (‘i’) and otherwise physiologic mechanisms (‘ii’) may play a predominant role. However, with disease progression, more and more additional oncogenic signaling molecules (‘iii’) and pathways become activated [197-200]. Thus, in advanced phases of a malignancy, additional signaling cascades and networks may play a more and more decisive role in CSC/LSC expansion and resistance. All three classes of molecules may contribute to CSC/LSC resistance, and all three have been considered as potential targets of therapy in solid tumors and leukemias [7,14,16,28,198,201,202].

In the past 15 years, several of the driver kinases have been identified as major targets of therapy. The highlighting example is CML where BCR/ABL-targeting tyrosine kinase inhibitors (TKI) induce major and long-lasting responses [203]. Other similar treatment concepts are emerging in other types of cancers and leukemias as well as in lymphomas. However, it has also been described that in most tumor models, NSC (CSC/LSC) cannot be eradicated completely using these drugs [11,24,28,130,204] as CSC/LSC often grow and survive independent of the primary (major) driver lesion, such as BCR/ABL in CML [204,205].

During the past few years, several major attempts, supported by next-generation sequencing approaches, have been made to reveal additional molecular lesions and the resulting signaling cascades and to define additional target pathways in CSC/LSC [206,207]. Indeed, a number of different signaling pathways - often shared by normal and neoplastic stem cells - have been described to play a role in the evolution and maintenance of CSC/LSC. Several of these pathways have been implicated in stem cell self-renewal. One of these pathways is the Wnt/ß-catenin pathway. This pathway is involved in the maintenance of self-renewal of NSC in leukemias and melanoma as well as in breast, lung, and liver cancers [119,198,208-211]. The Notch signaling pathway has been implicated in self-renewal of CSC in breast cancer, colon cancer, and glioblastoma [201,212-214]. The hedgehog-signaling pathway is also considered to contribute to self-renewal of CSC in various malignancies, such as glioblastoma, breast cancer, colon cancer, pancreatic cancer, and also in leukemias [215-219]. Other signaling pathways may be involved in the regulation of proliferation, survival, and differentiation of CSC. These pathways include, among others, the PI3 kinase-mTOR pathway, the RAS-RAF-MEK-ERK pathway, or the JAK-STAT pathways [196,220-223].

**Role of the microenvironment and cell-cell interactions**

Depending on the stage and type of malignancy, growth and self-renewal of NSC (CSC/LSC) rely on a permissive microenvironment, the CSC niche [4,14,45,72,224,225]. In an early phase of cancer evolution, the CSC niche may regulate growth and self-renewal of premalignant NSC in a similar or in the same way as that of normal stem cells [54,211-216,226,227]. Relevant molecules contributing to stem cell niche interactions in healthy tissues and in ‘premalignant neoplastic states’ include adhesion molecules, chemotactic factors, cytokines, and growth factor receptors [99,225,228-235] (Figure 1). In addition, the local electrolyte milieu, the Ca$^{2+}$ gradient as well as hypoxia may contribute to stem cell niche interactions and stem cell self-renewal in normal and (pre)malignant conditions [225].

**Stem cell homing and abnormal spread of NSC/CSC**

Depending on the organ system, homing of stem cells is a physiologic process [225,236-239]. Likewise, normal hematopoietic stem cells are detectable in the peripheral blood and undergo homing in various organs. In most solid organs, however, stem cells do not undergo redistribution and homing, unless these cells transform to metastasizing CSC. Stem cell homing of normal hematopoietic stem cells and LSC is a multi-step process and the same holds true for the invasion-metastasis cascade of CSC [240,241]. Several different molecules are involved in the homing and invasion process, including selectins and selectin-ligands, integrins and their receptors, and other cell-cell and matrix-binding molecules [240,242]. However, ordered expansion and redistribution from and into the stem cell niches in various organs is usually deregulated in premalignant NSC and malignant CSC/LSC [84,99,225,228-235]. In the normal and leukemic bone marrow, several specific molecular interactions that may contribute to stem cell homing (to the niche) have been identified. These include, among others, SDF-1-CXCR4 interactions, SCF-KIT interactions, and Notch-Notch-ligand interactions (Figure 1) [64,139,225]. In solid tumors, interactions between CSC and the CSC niche are less well defined. One important type of molecules may be cytoadhesion receptors, including integrins, selectins, CD44, or members of the cadherin family. Most of these homing receptors, including chemokine receptors and ligands of matrix molecules such as L1 or CD44, have been detected on CSC [228,229,243]. Likewise, L1 is expressed on the edges of invasive colon cancers and its metastases [230,231] and the same holds true for CD44 and CD133, suggesting that these molecules play a role in tumor invasion and thus disease progression [99,230-232].

During progression of a tumor or leukemia, CSC/LSC may no longer depend on their interaction with the
Rather, CSC/LSC often expand and redistribute from local sites to other organs to cause metastasis. In epithelial tumors, CSC redistribution is facilitated by the so-called epithelial-mesenchymal transition (EMT), a process that is associated with a loss of specific (adhesive) interactions between cancer cells and the surrounding microenvironment [233,244,245]. Several different molecules, including E-cadherin and L1, have been implicated in the process of EMT in solid tumors [230-233]. Since EMT may also involve CSC, metastasis formation is directly linked to EMT. In hematopoietic neoplasms, similar mechanisms may apply during disease evolution. However, so far, little is known about specific alterations in CSC niche interactions in these malignancies. In CML, LSC have been described to exhibit an adhesion defect that may explain the LSC escape from the bone marrow niche, and subsequent extramedullary spread of progenitors, which is a pathognomonic finding in this type of leukemia [234,235,246].

The endosteal and the vascular stem cell niche in the bone marrow

In the normal bone marrow (BM) and in hematopoietic neoplasms, two types of stem cell niches have been postulated, a vascular niche and an endosteal (osteoblastic) stem cell niche (Figure 1). Both niches are considered to play a role in SC homing and SC self-renewal. A number of SC receptors and their ligands regulate quiescence, self-renewal, proliferation, differentiation, and homing of SC. Relevant ligands are expressed in niche-related cells, including vascular endothelial cells, endosteal cells, and osteoblasts. Whereas several of these ligands are membrane-bound and act as homing receptors, some of them, such as stem cell factor (SCF) or stroma cell-derived factor-1 (SDF-1), can also be produced and released as soluble ligands and thus can act as chemotactic factors for SC. Abbreviations: OPN, osteopontin; HY-A, hyaluronic acid; Ang-1, Angiopoietin-1.
the endosteal stem cell niche is primarily represented by endosteal-lining cells and osteoblasts [225,247]. The endosteal niche is considered to provide a more hypoxic and hypercalcemic milieu than the vascular niche, which may also contribute to stem cell niche interactions [14,225,250-252] (Figure 1). Several different adhesion molecules, like hyaluronic acid, Jagged, N-cadherin, osteopontin, CAMs, VEGF, SCF, or SDF-1, are considered to contribute to stem cell homing in the niche [225,247-249]. Normal and neoplastic stem cells express receptors for these stromal ligand receptors (Figure 1).

Role of hypoxia

Hypoxia and hypoxia-inducible factors (HIF) may influence the fate and self-renewal capacity of stem cells in the micro-milieu of the stem cell niche in health and disease [14,225,250-254]. So far, little is known about the mechanisms through which hypoxia regulates self-renewal and proliferation of CSC. One important aspect may be that hypoxia upregulates not only HIF expression but also several angiogenic and growth-regulatory cytokines, such as SDF-1 (CXCR4) or VEGF [250, 255,256]. These cytokines may promote tumor-associated angiogenesis. It has also been described that hypoxia maintains a more stem cell-like state of progenitor cells in the BM by regulating key signaling pathways responsible for stem cell growth and survival, such as Notch or Oct4 [253,254,257,258]. This may also hold true for CSC/LSC in hypoxic areas in the centers of solid tumors [259]. Another important aspect is that hypoxia can trigger the production of reactive oxygen species (ROS) in neoplastic (stem) cells, which in turn leads to DNA breaks and thereby increases mutagenesis and thus the generation of more malignant subclones [260,261]. Thus, hypoxia may be a trigger of oncogenesis and malignant progression as well as CSC/LSC resistance [262-264].

Plasticity and subclone formation of NSC (CSC/LSC)

A remarkable aspect in the biology of neoplastic stem cells is plasticity and subclone formation during disease evolution which is relevant clinically as subclone formation is often associated with progression and drug resistance. Recent data suggest that in AML and CML, subclone formation is an early and frequent event in LSC development, and the same may hold true for other neoplasms, including solid tumors [26,54,128,129,131,206,220,265]. Plasticity is best explained by genetic instability. The excessive plasticity and subsequent formation of neoplastic subclones is somehow contradictory to the hypothesis that many (at least premalignant) NSC are quiescent cells. However, subclone formation is now considered to be a step-wise and long-lasting process, which may explain the formation of multiple CSC subclones with varying proliferative capacity (Figure 2) [28,48,54,128]. Subclone formation and plasticity of LSC in CML may also be associated with lineage commitment and differentiation or even a lineage switch. One good example is lymphoid or biphenotypic (mixed) blast crisis in Ph + CML [266-269]. In rare cases, subclone formation from LSC is excessive and may result in the development of two histologically unrelated but still monoclonal neoplasms [270-272]. Finally, it has also been reported that some of the hematopoietic neoplasms produce their own (clonal) microenvironment [273-275]. A related observation is ‘vasculogenic mimicry’ that involves the so-called ‘malignant Stromal cells’ or ‘malignant endothelial cells.’ Such stromal cell progenitors have recently been detected in several malignancies, including AML [276]. All these observations suggest that the leukemia-associated microenvironment, including the LSC niche, is a new emerging target of therapy.

Expression of molecular targets in NSC/CSC

An essential question in CSC research is whether certain therapeutic targets are expressed in or on CSC. Notably, targeting of CSC using drugs that can kill or permanently suppress these cells may be a pre-requisite for the development of new curative treatment approaches in cancers and leukemias [7,11,14,16,28]. However, unfortunately, in many instances, CSC and normal stem cells share the same target antigens [64]. As a result, CSC-targeting therapies often result in the occurrence of substantial adverse side effects such as prolonged cytopenia. In this regard, it is noteworthy that the only available curative drug-therapy in AML, which is polychemotherapy, is usually also associated with prolonged cytopenia. Therefore, current research is seeking novel markers and targets that are preferentially or even selectively expressed on CSC (LSC) but are not expressed (or less abundantly expressed) by normal stem cells [67,84,87]. Examples for surface markers/targets that have been described to be expressed primarily on LSC in myeloid leukemias, but less abundantly (or not at all) on normal stem cells, are CD25, CD26, CD33, CD47, CD52, CD96, CD123, IL-1RAP, and CLL-1 [65-69,72,73,85,277-280]. With regard to CD33 and CD52, clinically established targeting concepts are available [280-282]. Likewise, as assessed by in vitro and in vivo experiments, the CD52-targeting antibody alemtuzumab is able to kill LSC in AML and MDS [77]. Figure 3 shows the effect of alemtuzumab on AML LSC in vitro. However, unfortunately, normal stem cells also express low but detectable amounts of these surface antigens, and the respective drugs, gemtuzumab ozogamicin (GO, anti-CD33) and alemtuzumab (anti-CD52) have recently been removed from the oncologic market because of their toxicity profiles which may indeed result in part from their effects.
on normal stem cells [280-282]. There are also other antibody-based targeted drugs that are currently being developed, such as (among others) CLL-1, IL-1RAP, CD44, CD96, or CD123. The value of these agents is currently being tested preclinically and in clinical trials [283].

A number of different signaling molecules and survival molecules have been identified as potential targets in LSC/CSC. Among these are the PI3K, mTOR, MEK, Smoothened, Notch, Wnt, heat shock proteins, and Bcl-2 family members. Table 5 provides an overview of molecular targets expressed in CSC and LSC in various malignancies. During the past few years, several potent targeted drugs directed against the primary dominant oncoproteins of various tumors and leukemias have been developed. An interesting example is CML, where BCR/ABL blockers are applied successfully to suppress the growth and expansion of LSC [203]. However, even BCR/ABL TKI may not be capable of suppressing all LSC for a prolonged time period, because of stem cell resistance [11,19-23,204]. Nevertheless, the effects of BCR/ABL TKI in CML are a highlighting example of LSC suppression. Notably, in many patients in whom TKI treatment has led to a complete continuous molecular response, treatment discontinuation can be performed, and only a subset of these patients relapse whereas others remain BCR/ABL-negative over years, suggesting that many (clinically relevant) LSC had been eradicated [284].

**Intrinsic and acquired resistance of NSC/CSC**

Normal and neoplastic stem cells benefit from several repair mechanisms and defense systems through which these cells can escape or survive various stress reactions, toxin-exposure, or microbial attacks, and the same mechanisms are responsible for drug resistance [11,19-23,28,298,299]. In the context of neoplastic stem cells, intrinsic forms and acquired forms of resistance have been described. Intrinsic resistance is usually detectable in all CSC populations (subclones), including
premalignant NSC and CSC/LSC, whereas acquired resistance is usually found in newly generated, more malignant, subclones and their (subclone-specific) CSC/LSC in advanced neoplasms [11,19-23,28,41,306-312] (Table 6). In addition, the local organ-specific microenvironment, tissue hypoxia, and the interaction with the ‘CSC niche’ may contribute to the resistance of CSC/LSC [11,19-23,28,45,313].

A number of different mechanisms may underlie acquired drug resistance in CSC/LSC. One is genetic instability and the ‘mutation capacity’ of the malignant genome, resulting in a plethora of mutations in critical target genes that can be detected in (more) malignant subclones in these patients [28,54,78,129,206,207,325]. These mutations may occur in an early phase (or even prephase) of the disease. They may develop in most, many, or only a few subclones and may either be detectable at diagnosis (prominent subclone/s) or they remain undetectable for a longer time period because they develop in slowly cycling NSC that are only capable of generating small-sized subclones [26,28,54,128,325]. Nevertheless, as soon as these small-sized subclones acquire a sufficient number of additional hits (mutations), they can expand and develop into an overt disease in which neoplastic cells and CSC exhibit acquired resistance [26,28,54,128,325]. The use of targeted drugs must lead to a selection of these more malignant subclones over time. Mutations leading to drug resistance may occur in a number of different genes. Likewise, mutations in various tyrosine kinases may contribute to resistance against oncoprotein-targeting drugs [326-328]. The best studied model is CML, where multiple mutations in the BCR/ABL kinase domains have been identified in Imatinib-treated patients [326-328]. Such mutations have been detected in virtually all oncogenic kinases that play a key role in human leukemogenesis or myeloproliferation and also in most other tumor models [329].

Other mechanisms of acquired resistance include the amplifications of target genes (overexpressed targets) or activation of additional pro-oncogenic molecules (Table 5) [330-334]. These types of resistance are usually associated with a poor prognosis and are often accompanied by cytogenetic evidence of clonal evolution. Likewise, in CML and AML as well as in MDS, a complex karyotype usually indicates an unfavorable prognosis [334-336].

Can we translate the CSC concept into clinical practice? Most of the conventional anti-cancer agents currently used in daily practice or in clinical trials are primarily acting on rapidly dividing cells that make up the bulk of the tumor, whereas most CSC (and premalignant NSC)
Table 5 Molecular targets detectable in neoplastic stem cells (NSC)

| Target type          | Molecular target example | Potentially relevant as NSC-target in | Targeted drug example |
|----------------------|--------------------------|--------------------------------------|-----------------------|
| Surface antigens     | CD20                     | ALL, CLL                             | Rituximab [285,286]   |
|                      | CD33                     | CML, AML                             | GO [85,282]           |
|                      | CD44                     | AML                                  | mAb [72]              |
|                      | CD52                     | 5q-AML, CLL                          | Alemtuzumab [77,287]  |
|                      | CD123                    | AML                                  | mAb [69]              |
|                      | EGFR                     | Colon-Ca                             | Cetuximab [288]       |
|                      | ERBB2                    | Breast/Gastric/ Ovarian-Ca           | Trastuzumab [172]     |
| Cytokine receptors   | KIT                      | GIST, CML                            | Imatinib [203,289]    |
|                      | PDGFR                    | CEL, GIST                            | Imatinib              |
|                      | EGFR                     | Pancreas-Ca                          | Erlotinib [182]       |
|                      | ERBB2                    | Breast-Ca                            | Lapatinib [290]       |
| Signaling molecules  | Hedgehog                 | Basal cell carcinoma                 | Vismodegib [291]      |
|                      | BRAF                     | Melanoma                             | Vemurafenib [292]     |
|                      | BTK                      | CLL                                  | Ibrutinib [293]       |
|                      | mTOR                     | Glioblastoma, Renal cell carcinoma   | Temsirolimus [294,295]|
| Transcription factors| MYC                      | AML                                  | JQ1 [296]             |
| Niche-NSC-axis       | CD26/DPPIV               | CML                                  | Gliptins [84]         |
|                      | CD184/CXCR4              |                                      | Plerixafor [159]      |
|                      | VEGF-VEGFR               |                                      | Bevacizumab [297]     |
|                      | SCF-KIT-axis             |                                      | Imatinib [203]        |

Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; mAb, monoclonal antibodies; EGFR, epidermal growth factor receptor; Ca, carcinoma; GIST, gastrointestinal stroma cell tumor; CEL, chronic eosinophilic leukemia; PDGFR, platelet derived growth factor receptor; BTK, Bruton’s tyrosine kinase; mTOR, mammalian target of rapamycin; MDR-1, multidrug-resistance protein 1; CSA, cyclosporine A; DPPIV, dipeptidyl-peptidase IV; VEGF, vascular endothelial growth factor; SCF, stem cell factor.

Table 6 Mechanisms of drug resistance in NSC and strategies to overcome resistance

| Mechanism                        | Proposed strategy to overcome resistance | Examples |
|----------------------------------|------------------------------------------|----------|
| NSC quiescence                   | Antibody-based killing of NSC            | CD20, CD33, CD52, Bi-specific mAb [77,280,286] |
|                                  | Mobilization of the immune system against NSC | Vaccination [314], IL-2 + histamine [315] |
|                                  | NSC mobilization into the cell cycle     | Cytokine-priming [316] |
|                                  | CTLA-4 inhibition                        | Ipilimumab [317] |
|                                  | PD1 inhibition                           | Nivolumab [318] |
| NSC-niche interactions           | NSC mobilization out of the niche         | Plerixafor [159] |
|                                  | Redirection of NSC into the niche         | Gliptins (CML [84]) |
|                                  | Targeting of niche cells                 | Revlimid [319] |
|                                  | Targeting of Niche modulating-cytokines (for example, VEGF) or Cytokine (for example, VEGF) synthesis | Avastin [320], Rapamycin [295] |
| Enforced drug efflux             | Verapamil [321,322]                      | Blocking the efflux pumps | CSA |
| Expression of anti-apoptotic proteins | Blocking BCL-2 family members            | Obatoclax [323] |
|                                  | Blocking heat shock proteins (Hsp)        | Hsp70, Hsp90 [324] |

NSC, neoplastic stem cells; IL-2, interleukin-2; CSA, cyclosporine A; CML, chronic myeloid leukemia.
are not affected. High-dose chemotherapy and novel targeted drugs may be able to eliminate the bulk of the neoplasm and to eradicate most CSC (or LSC) in a given tumor or leukemia. These debulking agents are still very useful and instrumental in anti-cancer therapy. However, relapses may develop from a few residual, drug-resistant, premalignant (quiescent) NSC that exhibit intrinsic stem cell resistance. Notably, even if all CSC/LSC can be eradicated by drug therapy, (late) relapses can develop from such residual, mostly quiescent premalignant NSC [26,28,54,128,131,220,325]. In other words, many new drug therapies can eliminate the mass of CSC/LSC that have generated the dominant clone but are unable to eradicate all quiescent premalignant NSC forming smaller subclones [26,54,128,284]. These drugs may even lead to operational cures without having the potential to eradicate the disease completely [128,284]. The question is how relevant the residual (often quiescent) NSC are in these patients. Notably, not all types of MRD and MRD-specific NSC may be relevant clinically, even if they may expand to another dominant clone [28,54,128]. Likewise, in hairy cell leukemia, cladribine (2CdA) may not be able to eradicate all LSC, and most premalignant NSC may survive. However, because of the relatively slow growth rate and low mutation rate of NSC, full blown relapses are relatively uncommon; and if they occur (typically after 3 to 5 years), leukemic cells are again responsive to the same drug. By contrast, in AML, the mutation rate is high and relapses are always indicative of a poor outcome and are often associated with multidrug resistance. The same holds true for most solid tumors. In CML, several novel TKI may induce complete continuous molecular remissions (CMR) [337,338]. Even imatinib can induce long-term CMR in a smaller fraction of patients [284]. When TKI are discontinued in these patients, some of them will relapse but may again respond to imatinib or other new TKI [284]. The exact curative potential of imatinib and of the new TKI in CML remains unknown. In solid tumor, novel TKI have also been applied in clinical trials and some of these agents are rather promising. However, long-term remissions are usually not induced with these agents even when combined with chemotherapy. Overall, with a few exceptions, in most advanced solid tumors, no drug-based CSC-eliminating treatment approach has been developed so far. However, there are several examples where targeted drugs as single agents may lead to long-term disease control. One example is the gastrointestinal stroma cell tumors (GIST), where TKI have shown encouraging results [339-341]. Another example is renal cell carcinoma, where inhibitors of the PI3k-mTOR pathway have shown to exert major anti-tumor effects [342,343].

A general problem in cancer evolution is that many CSC/LSC and most or all premalignant NSC may be dormant cells, and that dormancy is often associated with intrinsic resistance. One possible way to overcome this type of resistance may be to apply targeted antibodies, especially antibody-toxin conjugates which often act independent of the cell cycle and thus can destroy even dormant NSC. Likewise, in several types of lymphomas, the addition of pan-B-cell-targeting antibodies has substantially improved cure rates and the overall outcome (survival) in these patients [287,344,345]. An alternative strategy is to mobilize dormant cells into the cell cycle or out of the niche (where dormancy may be propagated) [159,346]. Finally, dormancy of NSC/CSC may be overcome by exposure to cytokines that promote cell cycle progression in NSC/CSC. Another principal strategy may be to promote CSC/LSC exhaustion by inducing differentiation and maturation in these cells or by mobilizing the immune system against CSC/LSC.

A major problem is that in advanced cancer lesions, CSC not only exhibit intrinsic (natural) stem cell resistance but often also acquired drug resistance in more resistant and thus more malignant subclones [28,54,128]. One strategy to address the multiple mechanisms of resistance accumulating in advanced tumor lesion is to apply drug combinations. Another strategy is to combine conventional or targeted drugs with response modifiers or agents that mobilize tumor cells into the cell cycle. An alternative approach is to select targeted drugs that can overcome acquired drug resistance resulting from point mutations in critical target genes. Likewise, in CML, second-generation BCR/ABL TKI can often overcome imatinib resistance associated with BCR/ABL mutations [338,347,348].

Another aspect in CSC/LSC evolution is that resistance of CSC/LSC is often associated with specific interactions between these cells and CSC niche. One strategy to overcome this form of resistance is to mobilize CSC/LSC from the niche where stem cells are considered to be protected and thus less accessible to targeted drugs. One example is the SDF-1/CXCR4 axis that can be disrupted by the CXCR4 blocking agent Plerixafor [349,350]. Recent data suggest that Plerixafor cannot only mobilize normal hematopoietic stem cells from the bone marrow stem cell niche but also LSC and that Plerixafor-mobilized LSC may be more sensitive against certain anti-leukemic drugs [159,346]. However, it remains unknown whether all LSC can be mobilized by Plerixafor, whether the mobilization is associated with a rebound of more rapidly growing LSC in the niche and whether addition of Plerixafor to conventional chemotherapy will indeed increase response and cure rates in patients with AML or other leukemias. In addition, more recent data suggest that in certain forms of leukemias (CML), LSC are already mobilized cells that can easily traffic between niches [84].
Recent data suggest that the vascular (arteriolar) stem cell niche is of particular importance for self-renewal of LSC [225,247-249]. Therefore, additional effects of targeted drugs on vascular cells or drug combinations employing anti-angiogenic agents are of considerable interest. One of these anti-angiogenic drugs is Lenalidomide, a major anti-angiogenic drug that produces major responses in various myeloid and lymphoid neoplasms, including 5q-MDS, multiple myeloma, and chronic lymphocytic leukemia. Several other anti-angiogenic drugs have been tested in hematopoietic and solid malignancies, with varying success. Encouraging results have been obtained when combining these agents with other anti-neoplastic agents. A remarkable observation is that the novel BCR/ABL TKI Nilotinib and Ponatinib (but not imatinib) are potent inhibitors of endothelial growth and angiogenesis [351]. Whether these additional effects of these TKI are responsible for their better efficacy in CML remains unknown. This is an attractive hypothesis, since their much stronger effects on BCR/ABL (when compared to imatinib) fail to explain their excellent clinical efficacy, as CML LSC are considered to survive independent of BCR/ABL [352,353]. Table 6 provides strategies aimed at overcoming LSC resistance in human malignancies.

### Summary and future perspectives

During the past few years several CSC/LSC-targeting concepts have been developed with the aim to establish more effective treatment approaches in applied oncology. However, although such novel treatment concepts are straight-forward, several questions remain. First, the complexity of the somatic aberration networks and of the resulting signaling cascades that drive oncogenesis during CSC/LSC evolution and may lead to CSC/LSC resistance. To address this aspect, the use of drug combinations or broadly acting drugs has been suggested and may be required to eliminate or suppress all relevant CSC/LSC populations in a given neoplasm. Novel treatment concepts have to take additional aspects into account, including intrinsic resistance, the related issue of CSC/LSC quiescence, and the interaction of CSC/LSC with their organ- and disease-specific microenvironment (CSC niche). Additional local factors such as hypoxia may also play a role in CSC/LSC resistance. The hope for the future is that we will be able to exploit our increasing knowledge about CSC/LSC, in order to define new treatment concepts, with the ultimate aim to eradicate CSC/LSC in various cancer types as well as in leukemias. In advanced, drug-resistant neoplasms, such treatment concepts may need to be combined with high-dose chemotherapy and/or stem cell transplantation.

### Abbreviations

BM: bone marrow; CD: cluster of differentiation; CML: chronic myeloid leukemia; CSC: cancer stem cells(s); CXCR-4: C-X-C chemokine receptor type 4; EMT: epithelial-mesenchymal transition; FGF: fibroblast growth factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; Her 2: human epidermal growth factor receptor 2; IL: interleukin; LSC: leukemic stem cell(s); NOD/SCID: non-obese diabetic mice with severe combined immunodeficiency; NOG: IL-2gamma chain-knock out NOG/NSG mice; NSC: neoplastic stem cell(s); NSG: NOD/SCID with loss-of-function-mutated IL-2Rgamma chain; PI3K: phosphatidylinositol-3 kinase; SCF: stem cell factor; SDF-1: stromal cell-derived factor 1; TKI: tyrosine kinase inhibitor(s).

### Competing interests

The authors declare that they have no competing interests.

### Authors’ contributions

AS, BTG, CCZ, and PV drafted the manuscript. KB, SC-R, IS, and HH helped to design the draft and provided figures and tables. All authors read and approved the final manuscript.

### Funding

This study was supported by the Austrian Science Funds, Project SFB-F4704-B20#, a cancer stem cell grant of the Medical University of Vienna and a research grant of the Initiative Krebsforschung Vienna, Austria.

### Author details

1 Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, Vienna A-1090, Wien, Austria. 2 Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Spitalgasse 23, Vienna 1090, Wien, Austria. 3 Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Wien, Austria. 4 Department of Radiation Therapy, Medical University of Vienna, Spitalgasse 23, Vienna 1090, Wien, Austria. 5 Department of Medicine I, Institute for Cancer Research, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Wien, Austria. 6 Department of Medicine I, Division of Clinical Oncology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Wien, Austria. 7 Department of Medicine I, Stem Cell Transplantation Unit, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Wien, Austria.

### Received: 15 October 2014 Accepted: 14 January 2015

Published online: 25 February 2015

### References

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
2. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460–6.
3. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267–84.
4. Galbise C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hammer B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69–82.
5. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–807.
6. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev. 2008;18:48–53.
7. Scarton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. 2009;31:1038–49.
8. Schulenburg A, Bramswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, et al. Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol. 2010;76:79–96.
9. Greaves M. Cancer stem cells: back to Darwin? Semin Cancer Biol. 2010;20:65–70.
10. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jameson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9393–44.
11. Vallet P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol. 2008;142(3):361–78.
12. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005;82:389–96.

13. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738–43.

14. Konopleva MV, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591–9.

15. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1823–33.

16. Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol. 2009;2:663–72.

17. Hollyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of interleukin-3. Blood. 2001;97:720–8.

18. Copland M. Chronic myelogenous leukemia stem cells: what's new? Curr Hematol Malig Rep. 2009;4:46–73.

19. Singh A, Setlurman J, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.

20. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45:872–7.

21. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.

22. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to RCR-ABL targeted therapies. Leukemia. 2007;21:926–35.

23. Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle. 2006;5:2862–6.

24. Welch JS. Mutation position within evolutionary subclonal architecture in AML. Semin Hematol. 2016;53:173–83.

25. Wang M, Wang Y, Zhong J. Side population cells and drug resistance in breast cancer. Mol Med Rep. 2015;10:3982–91.

26. Preuner S, Mitterbauer G, Mannhalter C, Herndlhofer S, Sper WR, Valpent P, et al. Quantitative monitoring of RCR-ABL1 mutants for surveillance of subclone-evolution, -expansion, -and -depletion in chronic myeloid leukemia. Eur J Cancer. 2012;48:233–6.

27. Schatton T, Murphy GF, Frank NY, Yamasu K, Warga-Gasser AM, Gasser M, et al. Identification of cells initiating human malignant melanoma. Nature. 2008;451:345–9.

28. Valpent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11:1156–71.

29. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;12041–50.

30. Besancon R, Valensa-Wittmann S, Puisieux A, de Fromentel CC, Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem. 2009;16:394–416.

31. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs. 2007;21:296–310.

32. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.

33. Lapidot T, Sirad C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature. 1994;367:645–8.

34. Cevreri G, Walter A, Kobelost N, Mihic-Probst D, Zipser M, Belloni B, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71:3098–109.

35. Pearson T, Greiner DL, Shultz LD. Creation of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3598–603.

36. Ishikawa F, Saito Y, Yoshida S, Harada M, Shultz LD. The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/Lt mice. Curr Top Microbiol Immunol. 2008;324:87–94.

37. Quintana E, Shcakleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–8.

38. Taussig DC, Mirsal-Moud F, Anjos-Afonzo F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112:560–75.
transplantation tolerance and treat autoimmune diseases. Blood. 2008;112:3543–53.

64. Florian S, Sonneck K, Hausworth AW, Krauth MT, Scherthaner GH, Sperr WR, et al. Detection of molecular targets on the surface of CD34+/CD38– stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47:207–22.

65. Mohsaver B, van Rhemen A, Kelder A, van der Pol M, Tenmijn M, Bachas C, et al. Identification of a small subpopulation of candidate leukemia initiating cells in the side population (SP) of patients with acute myeloid leukemia. Stem Cells. 2008;26(12):3059–67.

66. Blair A, Hogge DE, Alles LE, Lansdorp PM, Sutherland JL. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:1014–22.

67. van Rhemen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Mohsaver B, et al. The novel AML stem cell associated antigen CD11C aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2569–66.

68. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104:11008–13.

69. Jordan CT, Upchurch D, Silhavy SS, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–84.

70. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. J Biol Chem. 1990;265:2417–26.

71. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004;61:2924–31.

72. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemia stem cells. Nat Med. 2006;12:167–74.

73. Majet R, Cao MP, Alizadeh AA, Pang WW, Jaissal S, Gibbs JR KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:2869–99.

74. Kim JB, Ko E, Han W, Lee JE, Lee KM, Shin I, et al. CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer. 2008;8:118.

75. Saito Y, Kitamura H, Hjikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapeutic-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra19.

76. Taussig DC, Pearson DJ, Simpson C, Rohlmann AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloma markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106:4086–92.

77. Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, et al. Identification of candidate–CAM-1 (CD125) as a novel drug target in neoplastic stem cells in Spatients with MDS and AML. Clin Cancer Res. 2014;20 (13):3589–602.

78. Taussig DC, Vargaftig I, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukaemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(−) fraction. Blood. 2010;115:1976–84.

79. Nilsson L, Astrand-Grundstrom I, Anderson K, Anvidsson I, Holmland P, Byrder D, et al. Involvement and functional impairment of the CD34(+)CD38(−) Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100:2569–77.

80. De Smet D, Trullemans F, Jochmans K, Renmans W, Smet L, Heylen O, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–44.

81. Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci. 2011;68:5389–605.

82. Fukamachi H, Seol HS, Shimada S, Funasaka C, Baba K, Kim JH, et al. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS One. 2013;8:e72438.

83. Herrmann H, Cerny-Reiterer S, Gleunser KV, Blatt K, Herrlichhofer S, Rabitsch W, et al. CD34(+)CD38(−) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumabozogamicin. Haematologica. 2012;97:219–26.

84. Herrmann H, Cerny-Reiterer S, Gleunser KV, Blatt K, Herrlichhofer S, Rabitsch W, et al. CD34(+)CD38(−) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumabozogamicin. Haematologica. 2012;97:219–26.

85. Herrmann H, Cerny-Reiterer S, Gleunser KV, Blatt K, Herrlichhofer S, Rabitsch W, et al. CD34(+)CD38(−) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumabozogamicin. Haematologica. 2012;97:219–26.
clonogenic activity and stem cell-related gene expression profile in in vitro propagated gliblastoma multiforme-derived cell line with a PNET-like component. Folia Neuropathol. 2012;50:357–68.

107. Son MJ, Woolcock K, Narn DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human gliblastoma. Cell Stem Cell. 2009;4:440–52.

108. Suva ML, Rigg N, Stehe JC, Bauer K, Tercier S, Joseph JA, et al. Identification of cancer stem cells in Swain’s sarcoma. Cancer Res. 2009;69:1776–81.

109. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. Faseb J. 2011;25:2022–30.

110. Adhikari AS, Agarwal N, Wood BM, Porcella C, Ruiz B, Pochampally RR, et al. CD117 and Sca-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010;70:4602–12.

111. Tian J, Li X, Mi L, Liu T, Li J. CD271+ osteosarcoma cells display stem-like properties. PLoS One. 2014;9:e85949.

112. Meirelles K, Beneficat LA, Dombkowski D, Pepin D, Preffer Fl, Teixeita J, et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A. 2012;109:63–68.

113. Chen J, Wang J, Chen D, Yang J, Yang Z, Yang Y, et al. Evaluation of characteristics of CD44+ CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Biol. 2013;14:7.

114. Curlie MD, Therien VA, Cummings CL, Sergent PA, Koulouros CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human myeloma. Stem Cells. 2000;19:827–83.

115. Guo C, Liu H, Zhang BH, Cadanean RM, Mayle AM, Garraway IP, Epcom, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. PLoS One. 2012;7:e43219.

116. Hurt EM, Kawasaki BT, Klamann GJ, Thomas SB, Farar WL. CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98:756–65.

117. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008;26:2862–70.

118. Boklo AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466:135–7.

119. Wilson BJ, Saab KR, Ma J, Schatton T, Putz P, Zhan Q, et al. ABCG8 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res. 2014;74:4196–207.

120. Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, et al. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF. PLoS One. 2014;9:e98917.

121. Yui S, Nakamae K, Sato T, Nemozy M, Mizutani T, Zheng X, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5 (+) stem cell. Nat Med. 2012;18:618–23.

122. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Oncogene. 2014;34:4196–207.

123. Gotoh N. Control of stemness by fibroblast growth factor signaling in stem cells. Recent Patents Anticancer Drug Discov. 2009;4:54–7.

124. Gotsh N. Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells. Curr Stem Cell Res Ther. 2009;4:9–15.

125. Iaconcig L, Schulenberg A, Hudec X, Knoff M, Holmman K, Piazza G, et al. Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. Mol Carcinog. 2014. doi:10.1002/mc.22146.

126. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804–9.

127. Jiang X, Fujisaki T, Nicollin F, Berger M, Holyoake T, Elsasser W, et al. Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia. Leukemia. 2000;14:1112–21.

128. Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, et al. CD133+CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 2012;10:85.

129. Furusato B, Mohamed A, Uhlen M, Rhim JS, CXCR4 and cancer. Pathol Int. 2010;60:497–505.

130. Tavor S, Pettit I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol. 2010;20:178–85.

131. Tavor S, Pettit I, Porozov S, Avgidou A, Dar A, Leider-Trego L, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64:2817–24.

132. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparaj A, et al. Erythrophoetin receptor contributes to melanoma cell survival in vivo. Oncogene. 2012;31:1649–60.

133. Sinclair AM, Todd MD, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer. 2007;110:477–88.

134. Jellimann W, Bohlius I, Halleck M,nytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67:39–61.

135. Gonen M, Sun Z, Figueiredo ME, Patel JP, Abdel-Wahab O, Racitiissi K, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012;120:296–306.
et al. Journal of Hematology & Oncology

Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, et al. Journal of Hematology & Oncology

Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, et al. A

Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. c-kit point

Zhang Y, Guo Q, Zhao H, Zhao D, Wu X, Zhao W, et al. Expression of CXCR4

Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3

Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P,
et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes

Libermann TA, Nudaar HM, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of gliarial origin. Nature. 1983;314:193–7;

Hermansson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westmark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52:3213–9;

Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely

Abetov D, Mustapova Z, Saliev T, Bulanin D. Biomarkers and signaling pathways of colorectal cancer stem cells. Tumour Biol. 2015;doi:10.1007/s13277-015-3198-4.

Kogo K, Kiyokawa K, Kobayashi Y, Yuzuriha T, Nose S, Imai R, et al. Characterization of leukemia stem cells with the stem cell marker CD44 in the mouse model of severe combined immunodeficiency. Leukemia. 2011;25:1314–24.

Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. TGF-

Dubrovska A, Elliott J, Salamone RJ, Teglevaev GD, Stakhovsky AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One. 2012;7:e31226.

Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009;27:176–85.

Galvao AS, Donohue RE, Elghetany MT, Sheehan AM, Lu Y, Granatt GM, et al. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014;7:2575–30.

Kim HP, Frankel AE, Hodge DE. A diphteria toxin internalin-F3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemia progenitors from BCR/ABL-positive acute leukemia. Leuk Res. 2010;34:1035–42.

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011;25:1314–23.

Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20:649–79.

Lebedis C, Chen K, Fallavollita L, Boutros T, Bredt D. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of KGF-1 and EGF. Int J Cancer. 2002;100:2–8.

Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013;73:3489–93.

Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994;269:3469–55.

Pinto C, Di Fabio F, Siena S, Cascini S, Rojas Limpee FL, Cecarelli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastrointestinal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18:510–7.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol. 2013;4:308–18.

Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744–53.

Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009;27:176–85.

Galon A, Espinet E, Palomo-Ponce S, Tauﬄetto DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571–84.

Okamoto I, Araki J, Sato R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol. 2006;17:1028–9.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.

Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.

Libermann TA, Nudaar HM, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGFR receptor gene in primary human brain tumours of gliarial origin. Nature. 1983;314:193–7;

Hermansson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westmark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52:3213–9;

Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Ku Kang B, et al. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012;72:3828–38.

Gayshyer S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C, et al. Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer. 2013;109:1786–94.

Brownman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2839–45.

Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived viscan in the tumor microenvironment. Cancer Res. 2013;73:5016–28.

Dubrovskia A, Elliott J, Salameh RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One. 2012;7:e31226.

Singh S, Nannuru KC, Sadanandaam A, Varney ML, Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer. 2009;100:1638–46.

Karamboulas C, Alles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochem Biophys Acta. 1830(2013):2481–95.

Okuhashi Y, Itoh M, Nara N, Tohda S. Effects of combination of Notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res. 2011;31:893–6.

Sinclair A, Latif AL, Holoioke TL. Targeting survival pathways in chronic myeloid leukemia stem cells. Br J Pharmacol. 2013;169:1933–707.

Abetov D, Mustapova Z, Saleev T, Bulanin D. Biomarkers and signaling pathways of colorectal cancer stem cells. Tumour Biol. 2015;doi:10.1007/s13277-015-3198-4.

Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16:3153–62.

Dey A, Dhesayase D, Noubade R, French DM, Liu J, Chaurishiya MS, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012;337:1541–6.
14. Lee CW, Simin K, Plescia J, Guha M, Khan A, et al. Genetic variation of clonal architecture and propagating cells in leukemia. Nature. 2011;469:356–61.

15. Corbin AS, Agarwal A, Loriaux M, Cortes J, Dehghanizadeh S, Phelps J, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive chronic myeloid leukemia cells. Nat Med. 1996;2:561–6.

16. Corbin AS, Agarwal A, Loriaux M, Cortes J, Dehghanizadeh S, Phelps J, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive chronic myeloid leukemia cells. Nat Med. 1996;2:561–6.

17. Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Murohashi I, Nara N, Tohda S. Inhibition of Hedgehog signaling depresses self-renewal of pancreatic mammary stem cells. Cancer Res. 2006;66:6063–70.

18. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Evidence that transgene encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A. 2003;100:15853–8.

19. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009;106:1193–8.

20. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287–95.

21. Gursel Dl, Berry N, Bockkvar JA. The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery. 2012;70(19–21).

22. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66:6063–71.

23. Huang FT, Zhu-Suan YK, Zhuang YY, Wei SL, Tang J, Chen WB, et al. Inhibition of Hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. J Gastroen Hematol. 2012;7:43.

24. Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Murohashi I, Nara N, Tohda S. Inhibition of Hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. J Gastroen Hematol. 2012;7:43.

25. Phelips RA, Chidester S, DehghaniZadeh S, Phillips J, Sandoval IT, Rai K, et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell. 2009;137:623–34.

26. Korkaya H, Paulson A, Chasifa-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.

27. Kron J, Berry PA, Stowers MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate stem-like cells. Cancer Res. 2013;73:5288–90.

28. 2015) 8:16

29. 2008;68:4287–95.

30. Gursel Dl, Berry N, Bockkvar JA. The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery. 2012;70(19–21).

31. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66:6063–71.

32. Huang FT, Zhu-Suan YK, Zhuang YY, Wei SL, Tang J, Chen WB, et al. Inhibition of Hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. J Gastroen Hematol. 2012;7:43.

33. Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Murohashi I, Nara N, Tohda S. Inhibition of Hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. J Gastroen Hematol. 2012;7:43.

34. Phelips RA, Chidester S, DehghaniZadeh S, Phillips J, Sandoval IT, Rai K, et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell. 2009;137:623–34.

35. Korkaya H, Paulson A, Chasifa-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.

36. Kron J, Berry PA, Stowers MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate stem-like cells. Cancer Res. 2013;73:5288–90.
250. Konopleva M, Tabo Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia mechanisms and markers. Drug Resist Updat. 2009;12:103–13.

251. Sullivan WJ, Christofk HR. The metabolic milieu of metastases. Cell. 2015;163:363–4.

252. Xiang L, Gilles DM, Hu H, Takano N, Luo W, Lu H, et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2014;5:12509–27.

253. Clarke L, van der Kooi D. Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells. 2009;27:1879–86.

254. Moreno-Manzano V, Rodriguez-Jimenez FJ, Acena-Bonilla JL, Fuseto-Lardies S, Ercog S, Dopazo J, et al. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem. 2010;285:1333–42.

255. Levesque JP, Winkler IG, Hendl J, Willians B, Barbier V, et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor-165 in 8p11 patients. Blood Cells Mol Dis. 2004;32:195–64.

256. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman LE, et al. High oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007;67:9594–9.

257. Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733–6.

258. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, et al. Rac2-MRC-cell-generated ROS cause genotoxic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012;119:253–63.

259. Kanter HP, Warsch W, Delogu A, Bauer E, Esterbauer H, Casanova E, et al. ETV6-RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. Neoplasia. 2013;15:1292–300.

260. Warsch W, Grundschroder E, Berger A, Gilles L, Cerny-Reiterer S, Tigan AS, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukemia. Stem Cells. 2007;25:958–61.

261. Choy C, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Hypoxia induces the vascular niche. Nat Rev Cancer. 2007;7:733–4.

262. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2003;112:597–609.

263. Warsch W, Grundschroder E, Berger A, Gilles L, Cerny-Reiterer S, Tigan AS, et al. Hypoxia regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20:557–70.

264. Reid AG, van der Kooy D. Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells. 2009;27:1879–86.

265. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman LE, et al. High oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007;67:9594–9.

266. Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733–6.

267. Kluwe J, Weidmann HP, Warsch W, Delogu A, Bauer E, Esterbauer H, Casanova E, et al. ETV6-RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. Neoplasia. 2013;15:1292–300.

268. Warsch W, Grundschroder E, Berger A, Gilles L, Cerny-Reiterer S, Tigan AS, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukemia. Stem Cells. 2007;25:958–61.

269. Choy C, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Hypoxia induces the vascular niche. Nat Rev Cancer. 2007;7:733–4.

270. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2003;112:597–609.

271. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351:250–9.
of cells with high drug efflux capacity in human

8. Zuber J, Shi J, Wang E, Rappaport AR, Hermann H, Sison EA, et al. RNA
screen identifies B4D as a therapeutic target in acute myeloid leukaemia.
Nature. 2011;478:524–8.

9. Fons P, Herault JP, Delesque N, Tuyare J, Boni F, Herbert JM. VEGF-R2 and
nerveG-1 are involved in VEGF-A-induced differentiation of human bone
marrow progenitor cells. J Cell Physiol. 2004;202:351–9.

10. Shevington AJ, Li C. Expression of multidrug resistance genes in normal and
cancer stem cells. Cancer Invest. 2008;26:535–42.

11. Gottstein MM. Mechanisms of cancer drug resistance. Annu Rev Med.
2002;53:615–27.

12. Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP. The
poor response to imatinib observed in CML patients with low OCT-1 activity
is not attributable to lower uptake of imatinib into their CD34+ cells. Blood.
2010;116:2776–8.

13. Patrawala L, Calhoun T, Schneider-Boursard R, Zhou J, Claypool K, Tang DG.
Side population is enriched in tumorigenic, stem-like cancer cells, whereas
ABCGL2 and ABCG2 cancer cells are similarly tumorigenic. Cancer Res.
2005;65:2077–9.

14. Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, et al.
Enhanced MDRI expression and chemoresistance of cancer stem cells
derived from glioblastoma. Cancer Invest. 2009;27:901–8.

15. Yamamoto A, Shofuda T, Islam MO, Nakamura Y, Yamasaki M, Okano A, et al. ABCB1 is
predominantly expressed in human fetal neural stem/progenitor cells at an early development stage. J Neurosci. 2009;29:2615–23.

16. Jin W, Liu Y, Xu SG, Yin W, Liu J, Yang JA, et al. UHRF1 inhibits MDRI gene
transcription and sensitizes breast cancer cells to anticancer drugs. Breast
Cancer Res Treat. 2010;124:39–48.

17. Brendel C, Scharenberg A, Dohme R, Robey RW, Bates SE, Shulka S, et al.
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with
ABCGL2 on primitive hematopoietic stem cells. Leukemia. 2007;21:1267–75.

18. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA,
et al. Nuclear factor-kappaB is constitutively activated in primitive human
acute myelogenous leukemia cells. Blood. 2001;98:2301–7.

19. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et al. PTEN
maintains haematopoietic stem cells and acts in lineage choice and
leukaemia prevention. Nature. 2006;441:518–22.

20. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, et al. Pten
deficient colon cancer tumors in human colon cancer cells and improves the efficacy of oxaliplatin in p53-
deficient colon cancer tumors in vivo. Mol Cancer Ther. 2007;6:2868–78.

21. Clappier E, Gerby B, Sigaux F, Delord M, Touzi F, Hernandez L, et al. Clonal
selection in xenografted human T cell acute lymphoblastic leukemia
recapturates gain of malignancy at relapse. J Exp Med. 2012;208:653–61.

22. Hochhaus A. Chronic myelogenous leukemia (CML): resistance to tyrosine
kinase inhibitors. Ann Oncol. 2006;17 Suppl 10:274–9.

23. Draker BJ. Translation of the Philadelphia chromosome into therapy for
CML. Blood. 2008;112:4506–17.

24. Gore ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical
response to STI-571 cancer therapy caused by BCR-ABL gene
mutation or amplification. Science. 2001;293:786–80.

25. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Proc Natl Acad Sci U S A. 2005;102:11011–6.

26. Deininger M. Resistance and relapse with imatinib in CML: causes and
consequences. J Natl Compr Canc Netw. 2008;6 Suppl 2:211–21.

27. Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and
secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control.
2009;16:222–31.

28. Andreeff M, Konopleva M. Mechanisms of drug resistance in AML. Cancer
Treat Res. 2002;112:237–62.

29. Thomas X, Campos P, Le QH, Guyotat D. Heat shock proteins and acute
leukemias. Hematology. 2005;10:225–35.

30. Haase D, Gemming U, Schanz J, Pfeiffer BL, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and
correlation with subtypes: evidence from a core dataset of 2124 patients.
Blood. 2007;110:4385–95.

31. Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol.
2008;35:365–77.

32. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et al. Prognostic
significance of cytogenetic clonal evolution in patients with chronic
myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:1374–800.

33. Baccarini M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF,
et al. European LeukemiaNet recommendations for the management of
chronic myeloid leukemia: 2013. Blood. 2013;122:872–9.

34. Cortes JE, Kantarjian H, Shah NP, Buxy D, Mauro MJ, Flinn I, et al. Ponatinib
to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–14.

35. Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Nilotinib
versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med.
2011;365:6207–16.

36. Baccarini M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF,
et al. Ponatinib to activate anti-tumor immunity. Curr Opin Immunol.
2012;24:207–14.
344. Piosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803–43.

345. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613–26.

346. Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, et al. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood. 2012;120:2658–68.

347. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

348. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403–12.

349. Damon LE. Mobilization of hematopoietic stem cells into the peripheral blood. Expert Rev Hematol. 2009;2:717–33.

350. Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008;8:1797–804.

351. Hadzijusufovic E, Herndlhofer S, Aichberger KJ, Ghanim V, Suppan V, Cerny-Reiterer S, et al. Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph plus CML. Blood. 2011;118:1183–4.

352. Perl A, Carroll M. BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest. 2011;121:22–5.

353. Hamilton A, Helgason GV, Schemionek M, Zhang B, Mysina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501–10.